Late-stage trial of Moderna's mRNA seasonal flu vaccine completed
In an international study involving more than 40,000 adults over 50, Moderna's mRNA seasonal flu vaccine outperformed traditional vaccines in efficacy. The FDA is reviewing the drug, with a decision expected by August 5, which could make it the first approved mRNA flu vaccine in the US.
mRNA-1010: How Moderna rewrote the rules in the $8 billion flu vaccine market
On August 5, 2026, the FDA will deliver its verdict on the application for mRNA-1010, the first mRNA vaccine against seasonal flu. Behind this decision lies not just the fate of a single drug. It represents a tectonic shift in an industry where chicken eggs and multi-month production cycles have reigned for decades. But the main drama unfolded not in laboratories, but in regulatory corridors, and it is precisely the details that most commentators overlook.
The essence: what is really happening
Moderna has completed late-stage trials with results that are both impressive and raise questions. The Fluent study enrolled 40,703 people over 50—half received mRNA-1010, half a licensed standard vaccine. Relative efficacy was 26.6% (95% CI; 16.7%–35.4%), meeting all three criteria: non-inferiority, superiority, and even enhanced superiority with the lower bound of the confidence interval above 9.1%.
But the most interesting part happened not at the submission stage, but earlier. The FDA initially refused to accept the application—a refusal-to-file letter was personally signed by CBER Director Vinayak Prasad, which in itself is an exceptional case. The formal reason: Moderna used a standard-dose vaccine as a comparator rather than the "best available standard of care"—a phrase that does not even appear in FDA regulatory guidelines.
After a Type A meeting—a special procedure for resolving disputes between manufacturer and regulator—the FDA changed its position. Moderna proposed a bifurcated strategy: full approval for the 50–64 age group, accelerated approval for those 65 and older with a commitment to conduct a post-marketing study.
Timeline and context
The story of mRNA-1010 began long before January 2026, when applications were submitted to the FDA, EMA, Health Canada, and the Australian TGA. Moderna methodically built its evidence base through several phase studies. In P303, the vaccine showed superior seroconversion rates against all strains compared to both high-dose and standard vaccines. In P304—the very study with 40,703 participants—statistically significant superiority in clinical outcomes was achieved.
May 2026 brought publication in NEJM, the gold standard of evidence-based medicine. Concurrently, at ESCMID Global 2026 in Munich, data on the safety of repeat vaccination were presented: among 2,000 participants who received mRNA-1010 in two consecutive studies, no attenuation of immune response and no new safety signals were identified.
A separate storyline is the pandemic H5 vaccine on the same platform. CEPI awarded Moderna up to $54.3 million for phase 3, fitting into the global "100 Days Mission"—the ability to create a vaccine against a new pathogen within 100 days.
Who wins and who loses
Winners:
Moderna gains not just a new product but strategic diversification. After the decline in COVID vaccine revenue, the company urgently needs a new pillar—and the seasonal flu market is valued at $8 billion globally. Stéphane Bancel openly states this is "an important opportunity to support Moderna's growth in 2027 and beyond."
Patients over 50 are the main beneficiaries. Current vaccines leave a significant gap: even vaccinated people die from the flu. An additional 26.6% efficacy translates into thousands of prevented hospitalizations. With repeat vaccination, the immune response is even higher: GMFR 3.2–5.1 versus 1.5–2.4 for those receiving traditional vaccines.
Losers:
Sanofi, GSK, and Seqirus—manufacturers of traditional vaccines. Their business is built on egg-based and cell-based technologies with production cycles of 6–9 months. The mRNA platform reduces this to weeks, allowing more precise strain selection for a given season. GSK and Pfizer are already developing their own mRNA vaccines, but they are only in phase 2. A lag of at least 2–3 years in an industry where annual composition updates determine market share is critical.
The infrastructure for egg-based vaccine production—hundreds of millions of chicken eggs per year, specialized facilities—risks becoming obsolete. If the mRNA platform confirms superiority in the long term, traditional capacities face the same fate as film camera factories after the advent of digital cameras.
What the media isn't telling you
Insight one: the political subtext of the RTF letter.
February 2026. HHS Secretary Robert F. Kennedy Jr.—a figure with a long history of vaccine skepticism—has been in office for several months. The administration is backing away from recommendations for a third of childhood vaccines. And it is at this moment that the FDA issues a refusal-to-file for an mRNA vaccine, signed personally by the CBER director—not by a regular reviewer, as is usually the case. RBC Capital Markets analyst Luca Issi publicly stated that it is hard not to link this decision to the administration's attitude toward vaccines in general and mRNA technology in particular.
Moreover, the FDA letter cited no issues with the safety or efficacy of mRNA-1010. Moderna emphasizes that the study design was previously agreed upon with CBER. The regulator changed the rules post factum—an unprecedented signal to the entire industry about the increased unpredictability of the US regulatory landscape.
Insight two: asymmetry in reactogenicity.
The media focus on efficacy but overlook an important nuance. The frequency of local and systemic reactions with mRNA-1010 is significantly higher: injection site pain—65.8% vs. 29.8%, fatigue—45.1% vs. 20.3%, headache—37.8% vs. 18.0%, myalgia—35.4% vs. 11.6%. Most reactions were mild and transient, and the rate of serious adverse events was nearly identical (2.2% vs. 1.9%). But for public perception, this is critical: more noticeable side effects with annual vaccination could reduce adherence, especially among older adults with multimorbidity. Moderna faces a challenging communication task.
Insight three: the "repeat vaccination" problem.
The NEJM publication showed efficacy over a single season. But what will happen after 5, 10 years of annual mRNA vaccination? Data from ESCMID 2026 partially answer: in the group that received two doses of mRNA-1010, there was no attenuation of response. However, the sample is limited to 2,000 participants, and it is a retrospective analysis. The real answer will only come from long-term post-marketing studies.
Forecast: the next 30 and 90 days
30 days (mid-June 2026):
The FDA will work on the dossier under priority review. No public signals are expected—the regulator is extremely closed after the February scandal. However, activity on the ACIP (Advisory Committee on Immunization Practices) front can be anticipated: the committee will begin preparing recommendations in case of approval for the 2026/2027 season. ACIP's position will determine whether mRNA-1010 is included in federal purchasing programs and insurance coverage.
Concurrently, Moderna will ramp up production. Unlike egg-based vaccines, scaling mRNA production does not require biological systems—it is a chemical process that can be quickly deployed on existing post-COVID capacities.
90 days (mid-August 2026):
August 5 is the PDUFA date. I estimate the probability of approval above 75%. Arguments in favor:
- The NEJM publication with data from 40,703 participants created strong scientific legitimacy;
- Repeat vaccination data showed no safety issues;
- The FDA accepted the application after the Type A meeting—the regulator would not have done so if it planned to reject;
- A rejection would be politically toxic after the February RTF scandal and would create the impression that the agency is not acting based on science.
If approved, mRNA-1010 will reach the market for the 2026/2027 season, but with limited access—Moderna states it will be available for a "subset of patients." Full launch will occur in the 2027/2028 season.
Structural forecast for 2–3 years:
Approval of mRNA-1010 is not just the arrival of a new product in Moderna's portfolio; it triggers a chain reaction. GSK and Pfizer will accelerate their programs. Egg-based vaccine manufacturers will be forced either to invest in mRNA platforms or to consolidate. Regulators worldwide will face the need to revise requirements for clinical trials of flu vaccines—the comparator precedent has been set, and the industry needs clarity.
But the fundamental question remains open: will mRNA-1010 mark the beginning of the end for traditional flu vaccines, or will it be a technological offshoot with limited uptake due to reactogenicity and cost barriers? The answer will begin to emerge no earlier than the 2027/2028 season, when the vaccine enters real clinical practice rather than controlled study conditions.
— Editorial Team
